Boundless Bio, Inc. (BOLD)
NASDAQ: BOLD · Real-Time Price · USD
1.102
-0.008 (-0.72%)
At close: Mar 27, 2026, 4:00 PM EDT
1.110
+0.008 (0.73%)
After-hours: Mar 27, 2026, 4:00 PM EDT
Boundless Bio Employees
Boundless Bio had 28 employees as of December 31, 2025. The number of employees decreased by 36 or -56.25% compared to the previous year.
Employees
28
Change (1Y)
-36
Growth (1Y)
-56.25%
Revenue / Employee
n/a
Profits / Employee
-$2,078,464
Market Cap
24.87M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 28 | -36 | -56.25% |
| Dec 31, 2024 | 64 | -8 | -11.11% |
| Mar 31, 2024 | 72 | 0 | - |
| Dec 31, 2023 | 72 | - | - |
| Sep 30, 2023 | 71 | - | - |
| Jun 30, 2023 | 72 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| IGC Pharma | 70 |
| Kyntra Bio | 34 |
| Cue Biopharma | 29 |
| Longeveron | 25 |
| Tempest Therapeutics | 21 |
| ABVC BioPharma | 19 |
| NeuroSense Therapeutics | 17 |
| Serina Therapeutics | 13 |
BOLD News
- 12 days ago - Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026 - GlobeNewsWire
- 20 days ago - Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - GlobeNewsWire
- 25 days ago - Boundless Bio to Participate in the Leerink Global Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 2 months ago - Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway - GlobeNewsWire
- 4 months ago - Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 5 months ago - Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights - GlobeNewsWire
- 5 months ago - Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire